The increase was mainly due to an increase in headcount leading to higher wages, benefits and social security expenses as well as an increase in expenses for purchased research and development services, especially with respect to our BNT162 program. Phase 1/2 placebo-controlled, observer-blinded clinical trial, evaluating nucleoside-modified messenger RNA vaccine candidate (BNT162b1) in 45 subjects, and data from the ongoing Germany trial in 60 subjects. Dienstag, 11.08.2020 14:16 von dpa-AFX | Aufrufe: 1210 Biontech peilt weiter Impfstoffzulassung im Oktober an - Quartalszahlen Verschiedene Medikamente in Tablettenform (Symbolbild). BioNTech Neutral 10.11.2020 21:52:55 NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Biontech nach Quartalszahlen von 68 … BioNTech Aktie Klingelt morgen mit den Quartalszahlen der Wecker? ADRs) Quartalszahlen: 30.03.21: BioNTech SE (spons. ... Darüber hinaus verkündet das Unternehmen morgen seine Quartalszahlen für Q3 2020. The trial is a first-in-human (FIH), multi-site, open-label, Phase 1, dose escalation and expansion trial to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000/BNT131 administered intratumorally as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. von Finanztreff.de, 11.08.2020, 14:36 Uhr Aktien BioNTech Finanzen. BioNTech (ADRs Termine: Hier finden Sie die Termine-Seite für den Wert BioNTech (ADRs © 2021 GlobeNewswire, Inc. All Rights Reserved. Interest expense related to lease liability, Basic & diluted, loss per share for the period attributable to equity holders of the parent**. United States international:                +1 646 741 3167United States domestic (toll-free):      +1 877 870 9135Germany:                                         +49 692 2222 625. November 2020 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“), ein Unternehmen, das bahnbrechende Immuntherapien der nächsten Generation zur Behandlung von Krebs und Infektionskrankheiten entwickelt, hat heute Informationen zur Geschäftsentwicklung sowie die Quartalszahlen des am 30. In Q2 2020 BioNTech received an aggregate of €216.7 million ($236.0 million) in non-refundable upfront payments from the BNT162 collaboration agreements and equity investments with Pfizer and Fosun Pharma. BNT131 – BioNTech expects to provide a data update from the Phase 1 trial in solid tumors in 2H 2020. Quartalszahlen von Biontech kurz vor Antrag für Corona-Impfstoff. BioNTech ist heute ganz schön ordentlich gefallen. In addition, from the date of acquisition, our new U.S.-based subsidiary, BioNTech US Inc., contributed to our general and administrative expenses. September 2020 ergab sich ein Gesamtumsatz von 136,9 Millionen Euro, verglichen mit 80,6 Mio. Für die neun Monate bis zum 30. SAR441000/BNT131 is partnered with Sanofi. Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube. Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was €41.8 million for the three months ended June 30, 2020, compared to €25.8 million for the three months ended June 30, 2019. Adjustments to reconcile loss before tax to net cash flows: Depreciation and amortization of property, plant, equipment and intangible assets, Loss on disposal of property, plant and equipment, Decrease/(Increase) in trade receivable and contract assets, (Decrease)/Increase in trade payables, other liabilities, contract liabilities and provisions, Purchase of property, plant and equipment, Proceeds from sale of property, plant and equipment, Acquisition of subsidiaries and businesses, net of cash acquired, Proceeds from issuance of share capital, net of costs, Net increase/(decrease) in cash and cash equivalents, Change in cash resulting from exchange rate differences. Historische Entwicklung von Quartalszahlen der BioNTech Aktie (WKN: A2PSR2 / ISIN: US09075V1026) aus dem Sektor Biotechnologie, Informationen von boerse.de 08.05.2020 Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. im Vorjahreszeitraum. Der Wirkstoff-Forscher hat ordentliche Geschäftszahlen vorgelegt, die allerdings niemanden vom Hocker reißen. Conference Call and Webcast InformationBioNTech SE will host a conference call and webcast today at 08:00 a.m. 2020 Guidance: As a result of increased spending related to BNT162, BioNTech now expects net cash used in operating activities to be between €450M and €600M. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 31, 2020 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. Das Mainzer Biopharma-Unternehmen BioNTech und sein US-Partner Pfizer wollen bei einem Erfolg der … Mainz, Germany, November 3, 2020 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2020 on Tuesday, November 10th, 2020. BioNTech: Die Quartalszahlen sind da! Moderna’s Coronavirus Treatment Transforms Body Into Vaccine … ** Numbers of shares for calculating the earnings per share for the three and six months ended June 30, 2019 have been adjusted to reflect capital increase due to 1:18 share split which occurred on September 18, 2019. In addition, from the date of acquisition, the new U.S.-based subsidiary, BioNTech US Inc., contributed to our research and development expenses. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Received Fast Track designation for BNT162b1 and BNT162b2 from the U.S. Food and Drug Administration (FDA). BNT122 – BioNTech and Genentech reported a data update for the Phase 1a and 1b trial in multiple solid tumors in June 2020 as part of the American Association for Cancer Research (AACR) Virtual Annual Meeting II. As a monotherapy and in combination with atezolizumab, RO7198457 (BNT122/RG6180) was observed to have a manageable safety profile and to induce significant levels of neoantigen-specific immune responses, even in late-stage, heavily pre-treated patients. Deshalb steigt die Anspannung vor dem 11.08.2020 – an diesem Tag will BioNTech die Zahlen zum Q2 veröffentlichen, die keine großen Überraschungen enthalten sollten, da BioNTech bisher “nur” forscht und noch keine nenneswerten Umsätze erzielt – plangemäß. BioNTech: Die Quartalszahlen sind da! The data to be presented will include safety, tolerability and pharmacodynamic biomarkers. Im aktuellen Geschäftsjahr muss wiederum … BNT211 – Initiation of a Phase 1/2a open-label, multi-site dose escalation and dose expansion basket trial with or without a CLDN6 CARVac immunotherapy is expected in 2H 2020. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Lesen Sie jetzt „Kurz vor Antrag für Impfstoff: Biontech legt Zahlen vor“. For more information, please visit www.BioNTech.de. All agreements are subject to clinical success and regulatory approval. Quartalszahlen-0,1715 EUR: Q4 2020: 06.04.2021 (e)* Quartalszahlen: 1,7343 EUR: Q1 2021: 18.05.2021 (e)* Quartalszahlen: 2,5251 EUR: Q2 2021: 17.08.2021 (e)* Quartalszahlen… Die US-Bank JPMorgan hat das Kursziel für Biontech nach Quartalszahlen von 68 auf 90 US-Dollar angehoben, die Einstufung aber auf 'Neutral' belassen. Interim Condensed Consolidated Statements of Cash Flows, 190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png. BioNTech to Report Third Quarter 2020 Financial Results and Operational Update on November 10, 2020. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof. To participate in the conference call, please dial the following numbers 15-20 minutes prior to the start of the call and provide the Conference ID: 1963889. Unter dem Strich hat Biontech deshalb Verlust gemacht: Minus 210,0 Millionen Euro im dritten Quartal, nach einem Verlust von 30,1 Millionen Euro im Vorjahresquartal, stehen in den Büchern. Released data from the ongoing U.S. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call. General and Administrative Expenses: General and administrative expenses were €18.8 million for the three months ended June 30, 2020, compared to €14.6 million for the three months ended June 30, 2019. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page of the Investor Relations section of the Company’s website at https://biontech.de/. BioNTech anticipates that existing cash and cash equivalents, the net proceeds from the recent underwritten offering and the expected net proceeds from the private investment announced in June 2020 will enable the Company to fund operating expenses and capital requirements through at least the next 24 months. Nachrichtenquelle: 4investors | 11.05.2020, 14:17 | 511 | 0 | 0 On June 29, 2020, BioNTech announced the signing of a private investment of €223.9 million ($250.7 million, On June 11, 2020, the European Investment Bank (EIB) and BioNTech entered into a €100.0 million ($112.0 million. November 03, 2020 09:00 ET | Source: BioNTech SE. MAINZ, Germany, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and infectious diseases, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020. “We made significant progress in the second quarter toward our goal of advancing our oncology programs and toward bringing a COVID-19 vaccine to market as quickly as possible.  I am incredibly proud of our team, who has worked tirelessly to initiate our BNT162 Phase 2b/3 trial in record time and put us in a position to seek regulatory review as early as October of this year, if our trials are successful,” said Ugur Sahin, BioNTech’s CEO and Co-founder. Certain holders irrevocably agreed not to transfer or exercise their rights in the rights offering, and the shares underlying those rights were offered in the underwritten offering. 11.08.2020 08:11 Uhr - Autor: Michael Barck auf Twitter Heute wird BioNTech Quartalszahlen vorlegen. BNT311 – BioNTech expects to provide a data update in 2H 2020, which will include dose-escalation data from the Phase 1/2 trial in multiple solid tumors for GEN1042/BNT311 (PD-L1x4-1BB). ET (2:00 p.m. CET). Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected cash usage for 2020 and beyond; our anticipated cash runway; the timing, completion and extent of subscription of the rights offering; the planned next steps in BioNTech’s pipeline programs and specifically including, but not limited to, statements regarding plans to initiate clinical trials of BioNTech’s product candidates; expectations for data announcements with respect to BioNTech’s clinical trials; the timing for any potential emergency use authorizations or approvals for BNT162; and our ability to scale-up manufacturing capacity for BNT162 and supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. multilang-release. For the period of six months ended June 30, 2020, total revenue was €69.4 million, compared to €51.9 million for the comparative prior year period. BNT122 – BioNTech expects to provide an enrollment update from the Phase 2 trial (IMCODE-001) in first line melanoma in 2H 2020 with an interim data update anticipated in 2H 2021. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BNT111 – On July 30, BioNTech announced the publication of interim Phase 1 data for BNT111, the Company’s lead mRNA-based FixVac cancer vaccine program, in, BNT111 – On July 31, BioNTech and Regeneron Pharmaceuticals, Inc. announced a strategic collaboration to jointly conduct a randomized Phase 2 study for the treatment of melanoma that has progressed after prior PD-1 blockade, utilizing BNT111 FixVac and Regeneron’s Libtayo. The primary objectives will be to evaluate the safety and feasibility of administering BNT221 to patients. Die Corona-Infektionszahlen sind … September 2020 endenden Quartals … The rights offering had no accounting impact within the second quarter 2020. BioNTech SE (spons. Initiation of a Phase 1 study for BNT162b1 to evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval in China.